Seeking Alpha
13 Sept 2026, 11:30 UTC · 5h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
LISRAYA has received regulatory approval, providing ROIV with a commercial foundation. — Product approval transitions a company from R&D to revenue generation, significantly reducing binary risk.
+0.60ROIV's pulmonary candidate mosliciguat is currently awaiting the outcome of subsequent Phase 3 trials. — Phase 3 results are critical catalysts that determine the commercial viability of a potential pulmonary franchise.
+0.30Brepocitinib has the potential to expand into a broader immunology franchise through additional indications. — Expanding indications increases the total addressable market (TAM) for the drug, though it remains speculative.
+0.20Which stocks this story touches
Continue reading
5 related stories
Search tags
The company received a commercial foundation via LISRAYA approval and has promising assets in immunology and pulmonary health.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
20h ago
